Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) for aficamten, which could impact investors who acquired the company's securities during the specified class period [1][8]. Allegations - The lawsuit claims that Cytokinetics misrepresented the timeline for the NDA submission and approval process for aficamten, stating that FDA approval was expected in the second half of 2025 with a PDUFA date of September 26, 2025 [8]. - The company allegedly failed to disclose significant risks, particularly the non-submission of a required Risk Evaluation and Mitigation Strategy (REMS), which could lead to delays in regulatory approval [8]. Key Dates - Investors must contact the law firm before November 17, 2025, to be considered for the lead plaintiff motion deadline [4]. Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP, established in 1888, has extensive experience in securities litigation and aims to protect the rights of investors who have suffered financial harm due to misrepresented statements [5].